Corcept Therapeutics

Manager, Marketing Operations, Endocrinology Division

Remote

Auto‑apply with AI Apply

Not SpecifiedCompensation

Junior (1 to 2 years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, Biotechnology, HealthcareIndustries

Requirements

The ideal candidate should possess a Bachelor’s degree in Marketing, Business Administration, or a related field, with a minimum of 5 years of experience in marketing operations, preferably within the pharmaceutical or healthcare industry. Strong organizational skills, attention to detail, and the ability to manage multiple projects simultaneously are essential. Experience with contract management, vendor onboarding, and budget tracking is also required.

Responsibilities

As the Marketing Operations Manager, you will support contract and PO processing for the Endocrinology Marketing team, track and manage contract timelines, coordinate new vendor onboarding, support Speaker Bureau audit tracking, maintain quarterly HCP activity tracking, and partner with analytics teams to uncover actionable insights. You will also oversee materials warehouse and online fulfillment site operations, manage promotional materials, track vendor budgets, and provide field support. Additionally, you will administer and optimize Veeva PromoMats workflow and manage the Content Review Team’s daily operations.

Skills

Contract Management

PO Processing

Vendor Onboarding

Audit Tracking

Sunshine Act Reporting

Data Analysis

Budget Management

Inventory Management

Operational Coordination

Corcept Therapeutics

Develops cortisol modulators for medical conditions

About Corcept Therapeutics

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Key Metrics

Menlo Park, CaliforniaHeadquarters

1998Year Founded

$39.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Remote Work Options

Flexible Work Hours

Risks

Teva's antitrust lawsuit could lead to legal expenses and market share loss.

Heavy reliance on Korlym makes Corcept vulnerable to market fluctuations.

Recent investments may pressure Corcept for short-term financial performance, impacting R&D.

Differentiation

Corcept specializes in cortisol modulation, a niche with few direct competitors.

Korlym is the first FDA-approved treatment for Cushing's syndrome, a significant market advantage.

Corcept's extensive R&D has led to the discovery of over 1,000 selective cortisol modulators.

Upsides

Increased interest in cortisol therapies for mental health boosts Corcept's R&D prospects.

Advancements in drug delivery systems could enhance Corcept's product efficacy.

The FDA's fast-track designation supports Corcept's innovative cortisol-related treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free